BRPI0810175A2 - Inibidores pirididopirinidinona de p13k alfa - Google Patents

Inibidores pirididopirinidinona de p13k alfa

Info

Publication number
BRPI0810175A2
BRPI0810175A2 BRPI0810175-2A2A BRPI0810175A BRPI0810175A2 BR PI0810175 A2 BRPI0810175 A2 BR PI0810175A2 BR PI0810175 A BRPI0810175 A BR PI0810175A BR PI0810175 A2 BRPI0810175 A2 BR PI0810175A2
Authority
BR
Brazil
Prior art keywords
alpyrapyrypyrinydinone
inhibitors
alpyrapyrypyrinydinone inhibitors
Prior art date
Application number
BRPI0810175-2A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BRPI0810175A2 publication Critical patent/BRPI0810175A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0810175-2A2A 2007-04-11 2008-04-11 Inibidores pirididopirinidinona de p13k alfa BRPI0810175A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11
PCT/US2008/004807 WO2008127712A1 (en) 2007-04-11 2008-04-11 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0810175A2 true BRPI0810175A2 (pt) 2014-12-30

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0810175-2A2A BRPI0810175A2 (pt) 2007-04-11 2008-04-11 Inibidores pirididopirinidinona de p13k alfa

Country Status (25)

Country Link
US (2) US20100209340A1 (OSRAM)
EP (1) EP2142544B8 (OSRAM)
JP (1) JP2010523681A (OSRAM)
KR (1) KR20090130104A (OSRAM)
CN (1) CN101711249A (OSRAM)
AU (1) AU2008239596B2 (OSRAM)
BR (1) BRPI0810175A2 (OSRAM)
CA (1) CA2683820A1 (OSRAM)
CO (1) CO6241119A2 (OSRAM)
CR (1) CR11098A (OSRAM)
DO (1) DOP2009000242A (OSRAM)
EA (1) EA018964B1 (OSRAM)
EC (1) ECSP099722A (OSRAM)
ES (1) ES2425068T3 (OSRAM)
IL (1) IL201209A0 (OSRAM)
MA (1) MA31336B1 (OSRAM)
MX (1) MX2009010815A (OSRAM)
MY (1) MY150747A (OSRAM)
NI (1) NI200900183A (OSRAM)
NZ (1) NZ579945A (OSRAM)
SV (1) SV2009003389A (OSRAM)
TN (1) TN2009000389A1 (OSRAM)
UA (1) UA101315C2 (OSRAM)
WO (1) WO2008127712A1 (OSRAM)
ZA (1) ZA200906648B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
WO2007044729A2 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
ATE539752T1 (de) 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
HRP20110621T2 (hr) 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
ES2430614T3 (es) 2007-04-10 2013-11-21 Exelixis, Inc. Métodos de tratamiento del cáncer usando inhibidores de piridopirimidinona de PI3K alfa
EP2142543B8 (en) * 2007-04-11 2013-07-03 Exelixis, Inc. Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
EP2350070A1 (en) * 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
CA2785499C (en) * 2009-12-22 2017-05-02 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AU2011302196B2 (en) 2010-09-14 2016-04-28 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
AU2012332486A1 (en) 2011-11-01 2014-06-19 Arthur Decillis N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
DE602005002562T2 (de) * 2004-05-04 2008-01-31 Warner-Lambert Company Llc Pyrrolylsubstituierte pyridoä2,3-düpyrimidin-7-one und derivate davon als therapeutische mittel
EP1940839B1 (en) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha
JP5480503B2 (ja) * 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
ATE539752T1 (de) * 2006-08-16 2012-01-15 Exelixis Inc Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung
HRP20110621T2 (hr) * 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3

Also Published As

Publication number Publication date
CN101711249A (zh) 2010-05-19
NZ579945A (en) 2012-05-25
SV2009003389A (es) 2010-04-27
EA200970936A1 (ru) 2010-02-26
UA101315C2 (ru) 2013-03-25
ECSP099722A (es) 2009-12-28
KR20090130104A (ko) 2009-12-17
EP2142544B8 (en) 2013-07-03
CA2683820A1 (en) 2008-10-23
TN2009000389A1 (en) 2010-12-31
US20130343988A1 (en) 2013-12-26
ZA200906648B (en) 2010-04-28
WO2008127712A1 (en) 2008-10-23
AU2008239596B2 (en) 2013-08-15
ES2425068T3 (es) 2013-10-11
EA018964B1 (ru) 2013-12-30
IL201209A0 (en) 2010-05-31
NI200900183A (es) 2010-10-05
JP2010523681A (ja) 2010-07-15
US20100209340A1 (en) 2010-08-19
MY150747A (en) 2014-02-28
CR11098A (es) 2010-01-27
EP2142544B1 (en) 2013-05-22
MX2009010815A (es) 2009-10-29
MA31336B1 (fr) 2010-04-01
DOP2009000242A (es) 2010-04-30
CO6241119A2 (es) 2011-01-20
AU2008239596A1 (en) 2008-10-23
HK1139941A1 (en) 2010-09-30
EP2142544A1 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
FIC20220047I1 (fi) Avalglucosidase alfa
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
CY2017016I2 (el) Αναστολεις πρωτεασωματος
NL300828I2 (nl) albutrepenonacog alfa
BRPI0810175A2 (pt) Inibidores pirididopirinidinona de p13k alfa
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
BRPI0806898A2 (pt) Inibidores de mek
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
EP2199714A4 (en) FRIDGE
EP2165130A4 (en) COOLER
EP2181297A4 (en) FRIDGE
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
BRPI0814797A2 (pt) Inibidores dna-pk
EP2144023A4 (en) Refrigerator
EP2128546A4 (en) FRIDGE
EP2208950A4 (en) COOLER
FI20085260A0 (fi) Tulisija
EP2317257A4 (en) FRIDGE
EP2267388A4 (en) FRIDGE
EP2141427A4 (en) COOLER
BRPI0811044A2 (pt) 2-morfolin-4-il-pirimidinas como inibidores de p13k.
BRPI0918564A2 (pt) inibidores
EP2218988A4 (en) COOLER
EP2198220A4 (en) Refrigerator

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.